Intech Investment Management LLC Has $3.33 Million Position in Artivion, Inc. $AORT

Intech Investment Management LLC grew its holdings in Artivion, Inc. (NYSE:AORT) by 268.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 73,104 shares of the company’s stock after buying an additional 53,282 shares during the quarter. Intech Investment Management LLC owned approximately 0.15% of Artivion worth $3,334,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Geode Capital Management LLC lifted its position in Artivion by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 998,327 shares of the company’s stock worth $45,542,000 after buying an additional 66,709 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Artivion by 37.2% in the fourth quarter. Legal & General Group Plc now owns 190,748 shares of the company’s stock worth $8,700,000 after acquiring an additional 51,704 shares during the last quarter. Summit Creek Advisors LLC acquired a new position in shares of Artivion during the fourth quarter worth approximately $6,425,000. Larson Financial Group LLC lifted its position in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares in the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of Artivion by 12.9% during the fourth quarter. ProShare Advisors LLC now owns 8,174 shares of the company’s stock valued at $373,000 after purchasing an additional 934 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Artivion news, SVP Jean F. Holloway sold 8,962 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $38.00, for a total value of $340,556.00. Following the sale, the senior vice president directly owned 185,095 shares in the company, valued at approximately $7,033,610. This trade represents a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.30% of the company’s stock.

Artivion Trading Down 5.1%

NYSE:AORT opened at $21.05 on Tuesday. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of 87.73 and a beta of 1.27. The business’s 50-day moving average price is $31.64 and its two-hundred day moving average price is $38.55.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on AORT. LADENBURG THALM/SH SH raised shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a report on Friday, April 10th. Stifel Nicolaus set a $45.00 price objective on Artivion in a research report on Monday. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Weiss Ratings restated a “hold (c-)” rating on shares of Artivion in a research report on Wednesday, May 20th. Finally, Citizens Jmp decreased their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a report on Friday, May 8th. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $46.17.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.